These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8300454)

  • 1. Natural history and response to treatment of minimal change nephrotic syndrome.
    Prabhakar KS; Prakash KC; Mani MK
    J Assoc Physicians India; 1993 May; 41(5):263-5. PubMed ID: 8300454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome.
    Nakayama M; Katafuchi R; Yanase T; Ikeda K; Tanaka H; Fujimi S
    Am J Kidney Dis; 2002 Mar; 39(3):503-12. PubMed ID: 11877569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effect of chlorambucil in steroid-dependent and cyclophosphamide-resistant minimal change nephrotic syndrome.
    Ueda N; Takahashi K; Akioka Y; Morooka M; Ogawa A; Tsuzuki K
    J Nephrol; 2009; 22(5):610-5. PubMed ID: 19809993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal change glomerular disease in Malaysian adults and use of alternate day steroid therapy.
    Wang F; Looi LM; Chua CT
    Q J Med; 1982; 51(203):312-28. PubMed ID: 7146313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children.
    Donia AF; Gazareen SH; Ahmed HA; Moustafa FE; Shoeib AA; Ismail AM; Khamis S; Sobh MA
    Nephrol Dial Transplant; 2003 Oct; 18(10):2054-8. PubMed ID: 13679480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Minimal change nephrotic syndrome in adults].
    Galicia Basart M; Vallés Prats M; Ferrer Prevosti E; Piera Robert L
    Med Clin (Barc); 1989 Feb; 92(7):250-3. PubMed ID: 2716406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesangial IgG in childhood minimal change disease: clinical relevance.
    Abu-Farsakh H; Berry PL; Hill LL; Powell D; Hawkins EP
    Clin Nephrol; 1993 May; 39(5):245-9. PubMed ID: 8513599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome.
    Kyrieleis HA; Levtchenko EN; Wetzels JF
    Am J Kidney Dis; 2007 May; 49(5):592-7. PubMed ID: 17472840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-center experience with cyclosporine for treatment of idiopathic minimal change nephrotic syndrome in children.
    Sabry A; El-Husseini A; El-Dahshan K; Sobh M
    Iran J Kidney Dis; 2009 Jul; 3(3):127-35. PubMed ID: 19617660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of mesangial IgM deposition in "minimal change" nephrotic syndrome.
    Vilches AR; Turner DR; Cameron JS; Ogg CS; Chantler C; Williams DG
    Lab Invest; 1982 Jan; 46(1):10-5. PubMed ID: 7054586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of remission in minimal lesion nephrotic syndrome after treatment with prednisolone and cyclophosphamide.
    Dundon S; O'Callaghan U; Raftery J
    Int J Pediatr Nephrol; 1980 Mar; 1(1):22-5. PubMed ID: 7343524
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term treatment of minimal-change nephrotic syndrome with cyclosporin: a control biopsy study.
    Clasen W; Kindler J; Mihatsch MJ; Sieberth HG
    Nephrol Dial Transplant; 1988; 3(6):733-7. PubMed ID: 3147414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience.
    El-Husseini A; El-Basuony F; Mahmoud I; Sheashaa H; Sabry A; Hassan R; Taha N; Hassan N; Sayed-Ahmad N; Sobh M
    Nephrol Dial Transplant; 2005 Nov; 20(11):2433-8. PubMed ID: 16204303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Good results of cyclophosphamide in steroid toxicity in the treatment of nephrotic syndrome caused by minimal-lesion glomerulopathy in childhood].
    de Moor R; de Jong M; Monnens L
    Ned Tijdschr Geneeskd; 1992 May; 136(18):876-80. PubMed ID: 1589052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
    Waldman M; Crew RJ; Valeri A; Busch J; Stokes B; Markowitz G; D'Agati V; Appel G
    Clin J Am Soc Nephrol; 2007 May; 2(3):445-53. PubMed ID: 17699450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
    Li X; Li H; Chen J; He Q; Lv R; Lin W; Li Q; He X; Qu L; Suya W
    Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difficult-to-treat nephrotic syndrome: management and outcome.
    Sumboonnanonda A; Chongchate N; Suntornpoch V; Pattaragarn A; Supavekin S
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S142-8. PubMed ID: 16856434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Longitudinal study in children with the nephrotic syndrome and minimal glomerular lesion].
    Martini RJ; Gomila A; Solanas G
    Bol Med Hosp Infant Mex; 1977; 34(5):1105-16. PubMed ID: 758027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotic syndrome preceding Hodgkin's disease by 42 months.
    Huisman RM; de Jong PE; de Zeeuw D; van Imhoff GW; van der Hem GK
    Clin Nephrol; 1986 Dec; 26(6):311-3. PubMed ID: 3802598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of pure diffuse mesangial hypercellularity in patients with proteinuria.
    Griveas I; Stavianoudakis G; Karanikas E; Gogos K; Nakopoulou L
    Ren Fail; 2009; 31(3):192-5. PubMed ID: 19288323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.